Citi Pharma Limited Stock

Equities

CPHL

PK0126201018

Pharmaceuticals

End-of-day quote Pakistan S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
26.38 PKR -3.33% Intraday chart for Citi Pharma Limited +7.19% +11.12%

Financials

Sales 2022 9.78B 35.11M 48.2M Sales 2023 12.4B 44.51M 61.09M Capitalization 4.88B 17.5M 24.03M
Net income 2022 636M 2.28M 3.13M Net income 2023 658M 2.36M 3.24M EV / Sales 2022 0.65 x
Net cash position 2022 1.05B 3.79M 5.2M Net Debt 2023 262M 941K 1.29M EV / Sales 2023 0.41 x
P/E ratio 2022
11.7 x
P/E ratio 2023
7.41 x
Employees 594
Yield 2022 *
-
Yield 2023
11.7%
Free-Float 45.19%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.33%
1 week+7.19%
Current month+13.76%
1 month+13.76%
3 months+20.90%
6 months+14.75%
Current year+11.12%
More quotes
1 week
24.11
Extreme 24.11
27.88
1 month
23.00
Extreme 23
27.88
Current year
20.01
Extreme 20.01
27.88
1 year
19.07
Extreme 19.07
28.35
3 years
19.07
Extreme 19.07
50.05
5 years
19.07
Extreme 19.07
50.05
10 years
19.07
Extreme 19.07
50.05
More quotes
Managers TitleAgeSince
Chief Executive Officer - 12-10-07
Director of Finance/CFO - 19-10-31
Director/Board Member - 20-10-12
Members of the board TitleAgeSince
Director/Board Member - -
Chairman - 12-10-07
Chief Executive Officer - 12-10-07
More insiders
Date Price Change Volume
24-04-30 26.38 -3.33% 3,049,061
24-04-29 27.29 +3.65% 6,006,637
24-04-26 26.33 +5.11% 7,668,526
24-04-25 25.05 +2.41% 2,881,181
24-04-24 24.46 +0.33% 564,089

End-of-day quote Pakistan S.E., April 29, 2024

More quotes
Citi Pharma Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. The Company's departments include API, formulation, and research and development. Its key products under the API segment include Paracetamol, Amoxicillin, Levofloxacin, Cefixime, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, Ibuprofen, and Ascorbic acid. The Company's formulation department produces tablets, liquids, and capsules. Its research and development activities deal with various forms ranging from the development of new chemical/drug entities to the evaluation of existing products for alternative indications. Its other products include Amlodopine, Nimesulide, Mefenamic Acid, Simvastatin, Ranitiddine as Hcl, and Levofloxicen(as Hemihydrate), among others.
More about the company

Annual profits - Rate of surprise